Harry Kirsch

CFO

Equibles does not estimate personal net worth.

Get an email with a short summary when Novartis AG publishes a filing, an earnings call transcript or a press release.

About Harry Kirsch

Harry Kirsch is recorded as CFO at Novartis AG (NVS). Harry Kirsch has spoken on 11 earnings calls across 1 company, most recently for Novartis AG on February 4, 2026. Novartis AG is classified in the Drug Manufacturers - General industry within the Healthcare sector.

Harry Kirsch on recent calls

“I now walk you through our financial results for the fourth quarter and the full year of 2025, which, as Vaz mentioned, was very strong despite mid-year significant U.S. generic entries.”

CFO, Novartis AG Q4 FY2025 Earnings Call · February 4, 2026

“I'll now go over the financial results for the third quarter, the first nine months, and the full year guidance. As a reminder, all growth rates are presented in constant currencies.”

CFO, Novartis AG Q3 FY2025 Earnings Call · October 28, 2025

“I'll now talk you through our financials for the second quarter and the first half, which reflects continued strong performance of our growth drivers and overall portfolio.”

CFO, Novartis AG Q2 FY2025 Earnings Call · June 30, 2025

“I will now talk you through our financials for the first quarter, which reflect a very strong start to the year. As always, my comments will refer to growth rates in constant currencies, unless otherwise noted.”

CFO, Novartis AG Q1 FY2025 Earnings Call · March 31, 2025

“I'll now discuss our financials for the fourth quarter and full year 2024, which, as Vas mentioned, has shown some of the strongest performance in our history. My comments will refer to continuing operations and growth rates in constant currencies unless noted otherwise.”

CFO, Novartis AG Q4 FY2024 Earnings Call · December 31, 2024